Vibecotamab is a Monoclonal Antibody owned by Xencor, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.

Vibecotamab(XmAb-14045) elicits anti-cancer activity. The therapeutic candidate is a T-cell dependent bi-specific antibody (TDB), which allow one arm to target B cell antigen CD123 while the other arm recruits T cells by binding to the CD3 of the T-cell receptor. T cells have a central role in cell-mediated immunity. The therapeutic candidate evokes immune system. The type I antibodies may trigger cell death via apoptosis. The type II antibodies trigger cell death via direct cell death.

The revenue for Vibecotamab is expected to reach a total of $627m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vibecotamab NPV Report.

Vibecotamab is originated and owned by Xencor.

Vibecotamab Overview

Vibecotamab(XmAb-14045) is under development for the treatment of hematologic malignancies such as relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, myelodysplastic syndrome  and chronic myeloid leukemia. It is administered intravenously. It is an extended bi-specific monoclonal antibody which contains both tumor antigen binding domain CD123 and cytotoxic T-cell binding domain (CD3 binding domain). The drug candidate is developed based on XmAb antibody engineering technology (bi-specific technology).

Xencor Overview

Xencor is a clinical stage biopharmaceutical company that focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. . Xencor is headquartered in Monrovia, California, the US.

The company reported revenues of (US Dollars) US$275.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$122.7 million in FY2020. The operating profit of the company was US$43 million in FY2021, compared to an operating loss of US$76.8 million in FY2020. The net profit of the company was US$82.6 million in FY2021, compared to a net loss of US$69.3 million in FY2020. The company reported revenues of US$27.3 million for the third quarter ended September 2022, a decrease of 9.5% over the previous quarter.

Quick View – Vibecotamab

Report Segments
  • Innovator
Drug Name
  • Vibecotamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.